Phosphatidylserine-Omega3

DIETARY_SUPPLEMENT3 trials

Sponsors

Tel-Aviv Sourasky Medical Center, Enzymotec, Çağlar Charles Daniel Jaicks

Conditions

ADHDAttention Deficit Hyperactivity Disorder (ADHD)Attention Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity Disorder

Phase 2

Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD

CompletedNCT00382616

Tel-Aviv Sourasky Medical CenterAttention-Deficit/Hyperactivity Disorder

Start: 2004-07-31End: 2005-01-31Target: 90Updated: 2006-11-07

The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder

CompletedNCT00418184

EnzymotecAttention Deficit/Hyperactivity Disorder (ADHD)

Start: 2007-03-31End: 2009-11-30Updated: 2014-03-12

Unknown Phase

Effects of Phosphatidylserine and DHA on Cognitive Performance in Children With ADHD

CompletedNCT07521449

Çağlar Charles Daniel JaicksADHD, Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2023-12-30End: 2025-06-01Updated: 2026-04-13

Related Papers

Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids.

2008-05-01100 citations